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Genomic occupancy of Runx2 with global
expression profiling identifies a novel dimension
to control of osteoblastogenesis
Hai Wu1, Troy W Whitfield2, Jonathan A R Gordon1, Jason R Dobson3,4, Phillip W L Tai1, Andre J van Wijnen5,
Janet L Stein1, Gary S Stein1 and Jane B Lian1*
Abstract
Background: Osteogenesis is a highly regulated developmental process and continues during the turnover and
repair of mature bone. Runx2, the master regulator of osteoblastogenesis, directs a transcriptional program essential
for bone formation through genetic and epigenetic mechanisms. While individual Runx2 gene targets have been
identified, further insights into the broad spectrum of Runx2 functions required for osteogenesis are needed.
Results: By performing genome-wide characterization of Runx2 binding at the three major stages of osteoblast
differentiation - proliferation, matrix deposition and mineralization - we identify Runx2-dependent regulatory
networks driving bone formation. Using chromatin immunoprecipitation followed by high-throughput sequencing
over the course of these stages, we identify approximately 80,000 significantly enriched regions of Runx2 binding
throughout the mouse genome. These binding events exhibit distinct patterns during osteogenesis, and are associated
with proximal promoters and also non-promoter regions: upstream, introns, exons, transcription termination site regions,
and intergenic regions. These peaks were partitioned into clusters that are associated with genes in complex biological
processes that support bone formation. Using Affymetrix expression profiling of differentiating osteoblasts depleted of
Runx2, we identify novel Runx2 targets including Ezh2, a critical epigenetic regulator; Crabp2, a retinoic acid signaling
component; Adamts4 and Tnfrsf19, two remodelers of the extracellular matrix. We demonstrate by luciferase assays that
these novel biological targets are regulated by Runx2 occupancy at non-promoter regions.
Conclusions: Our data establish that Runx2 interactions with chromatin across the genome reveal novel genes, pathways
and transcriptional mechanisms that contribute to the regulation of osteoblastogenesis.
Background
The development of bone tissue, new bone formation in
the adult, mineral homeostasis and maintenance of bone
mass are mediated by cells of the osteoblast lineage. These
bone forming cells progress through a highly regulated dif-
ferentiation program, with each subpopulation of cells ac-
quiring stage-specific phenotypes that are characterized by
distinct profiles of expressed genes [1]. Osteoblast com-
mitment and differentiation are dependent on the appro-
priate expression of Runx2 (Runt-related transcription
factor 2), the master regulator of bone formation [1-3].
Ablation of Runx2 in mice results in the absence of a
mineralized skeleton, and disruption of Runx2 function
causes bone defects in the human disorder cleidocranial
dysplasia [4,5]. Runx2 controls a complex gene-regulatory
network during osteoblastogenesis [5,6]. It upregulates a
variety of osteoblast lineage-specific genes, including Osx
(osterix), Ocn (osteocalcin), and Bsp (bone sialoprotein),
and represses the expression of non-osteoblast genes such
as PPAR-γ (peroxisome proliferator-activated receptor
gamma) and MyoD (myogenic differentiation), which are
required for adipogenic and myogenic commitment, re-
spectively [7-9]. Studies have demonstrated that Runx2
controls gene expression by interacting with multiple clas-
ses of co-regulatory factors [1,3,10]. In addition to the
traditional transcriptional mechanisms, several epigenetic
mechanisms have been identified for Runx2-mediated
gene expression. For example, Runx2 is retained on
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mitotic chromosomes as an epigenetic bookmarking factor
to maintain cellular identity after cell division [11]. A sig-
nificant body of evidence substantiates the contribution of
Runx2 towards the epigenetic regulation of gene expres-
sion during osteoblast differentiation, through interactions
with histone deacetylases [12], histone acetyltransferases
[13], and SWI/SNF complex components [14].
Runx2 has been shown to activate or repress gene expres-
sion through binding to cis-regulatory DNA elements, the
Runx motif (TGTGGT) located in or near gene promoter
regions [15]. Genome-wide binding profiles of the tran-
scriptional factor CTCF and lineage-specific transcription
factors, such as PPAR-γ, MyoD, and GATA3 (GATA bind-
ing protein 3), via ChIP-Seq (chromatin immunoprecipita-
tion followed by high-throughput sequencing) have helped
to delineate cis-regulatory networks that are critical for cell
lineage control in adipocytes, myocytes and T cells, respect-
ively [16-19]. These studies have highlighted the regulatory
importance of long-range interactions and binding of
phenotypic transcription factors to non-promoter genomic
elements. These findings have greatly expanded existing
paradigms of transcriptional regulation. In contrast, the en-
tire scope of Runx2 binding elements remains largely un-
known, hindering a comprehensive understanding of the
cis-regulatory network through which Runx2 regulates the
transcription program for bone formation.
Hence, we have characterized the genome-wide occu-
pancy of Runx2 by ChIP-Seq in MC3T3-E1 preosteoblasts,
a well-studied in vitro model for osteoblastogenesis [20].
Runx2 occupancy was determined at three hallmark stages
of osteoblast differentiation: proliferation, matrix depos-
ition, and mineralization. Analyses of these data demon-
strated that Runx2 occupancy on genes is differentiation
stage-dependent in both binding intensities and binding
regions, indicating a shift in the regulatory mechanisms
required for the entire program of osteoblastogenesis. By
coupling genome-wide Runx2 binding with gene expres-
sion profiling, we have identified new Runx2 targets that
were validated for functional activities of Runx2 binding in
both promoter and non-promoter regions. Our study of
Runx2 genome-wide occupancy establishes a foundation
for future investigation of the Runx2-controlled regulatory
network during bone formation and homeostasis.
Results
Runx2 dynamically occupies a wide range of genomic loci
during osteoblastogenesis
Runx2 is a known master activator of bone formation,
but thus far only a small number of osteoblast-specific
target genes have been characterized [2,5,6]. To identify
genome-wide occupancy of Runx2 in osteoblast lineage
cells, we performed ChIP-Seq using a Runx2-specific
antibody at stages during the in vitro differentiation of
MC3T3-E1 preosteoblasts (Figure 1). This in vitro cell
model recapitulates in vivo osteoblast differentiation and
therefore was used for ChIP-Seq studies [21]. Alkaline
phosphatase activity, an early osteoblast marker, in-
creased as cells proceeded from proliferation (day 0) to
matrix deposition (days 9 and 21) and decreased upon
mineralization (day 28), visualized by Von Kossa staining
(Figure 1A). Runx2 mRNA and protein levels signifi-
cantly increased during the initial stage of differenti-
ation. While the mRNA levels reached steady state,
Runx2 protein levels declined during late mineralization
(Figure 1B). Osteoblast phenotypic markers, including
the transcription factor Osx/Sp7 (osterix/Sp7 transcrip-
tion factor), a marker of committed osteoprogenitors,
Day 0 9 21 28
AL
P
Vo
n
 K
os
sa
A
B
Bsp
Akp2
Ocn
21 280 9 day
10000
1000
0
100
10
1
Osx
0
2
6
8
10
4
0 9 21 28day
Col1a1
re
la
tiv
e 
m
R
N
A 
e
xp
re
ss
io
n
C
0 9 21 28Day 14
Runx2
H3
0
2
6
8
10
4
0 9 21 28day
Runx2
re
la
tiv
e 
m
R
N
A 
le
ve
l
Figure 1 The differentiation stages of murine MC3T3-E1
preosteoblasts used for profiling studies. (A) Staining for alkaline
phosphatase (ALP) activity (upper panel) and mineralization (Von Kossa,
lower panel) in MC3T3-E1 cells during three stages of differentiation:
proliferation (day 0), matrix deposition (days 9 to 21), and mineralization
(day 28). (B) Protein (left panel) and mRNA levels (right panel) of Runx2
during osteoblastic differentiation of MC3T3-E1 cells. Histone H3 (H3) was
used as loading control for western blotting. (C) Expression profile of
osteoblast-related markers Osx/Sp7, Col1a1 (left panel), Akp2/Alpl (alkaline
phosphatase liver/bone/kidney), Bsp/Ibsp, and Ocn/Bglap2 (right panel) in
MC3T3-E1 cells during differentiation. Relative mRNA levels (versus day 0)
were determined by quantitative RT-PCR (reverse transcription PCR),
normalized by Hprt1 mRNA levels and plotted as mean values ± SEM
(standard error of mean) from three independent biological replicates.
The expression levels of the genes in (B,C) at days 9, 21, and 28 were
significantly upregulated when compared to those at day 0 (P<0.05, t-test).
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the extracellular matrix protein Col1a1 (collagen type I
alpha 1), and the specialized mineral binding proteins
Bsp/Ibsp (bone sialoprotein/integrin-binding sialoprotein)
and Ocn/Bglap2 (osteocalcin/bone gamma-carboxyglutamate
(gla) protein 2), displayed expression patterns consistent with
the progression of osteoblastogenesis [2] (Figure 1C).
We next isolated and sequenced DNA from chromatin
bound by Runx2. Sequence reads from Runx2 ChIPs and in-
put controls were mapped to the mouse genome. Statisti-
cally significant enrichments of Runx2 were identified by
MACS (Model-Based Analysis of ChIP-Seq) [22] (Additional
file 1). RefSeq annotations [23] were used to assign Runx2
enrichments to categories of genomic locations (with non-
overlapping definitions for transcriptional start site (TSS),
promoter, exonic, intronic, transcription termination site
(TTS), upstream and intergenic regions (see Figure 2 for
details; Additional file 2). As Runx2 protein levels changed,
the total number of Runx2 peaks changed accordingly
(Figure 2A, left panel). The overall distribution of Runx2
binding among the categories of genomic locations was rela-
tively unchanged during differentiation (Figure 2A, right
panel). Among genomic locations, Runx2 occupancy at pro-
moters showed the greatest variation from 17.6% at day 0 to
8.8% at day 9 (Figure 2A, right panel). The majority of
Runx2 binding occurred at intergenic and intronic regions
(Figure 2A,B). However, when compared with a randomly
sampled background distribution of genomic intervals
(Additional file 3), Runx2 binding displayed preferential en-
richment in a genic context, particularly at promoters and
exons. One exception was under-represented Runx2 bind-
ing at intergenic regions when compared to nonspecific or
random binding (Figure 2B). This relative enrichment of
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Figure 2 Genome-wide profile of Runx2 occupancy. (A) Distribution of Runx2 binding peaks across the mouse genome were classified into
six categories of genomic locations: exon, intron, promoter (-1 kb to +150 bp of TSS), upstream (-1 kb to -20 kb from TSS), TTS region (-150 bp
to -1 kb of transcription termination site), and intergenic region. Peak distribution was plotted at each time point by peak number (left panel)
and by the percentage of total peaks (right panel). (B) Differential Runx2 enrichment in the six categories of genomic locations compared to the
predicted Runx2 motif (see below), to random binding, or to binding of the transcription factor CTCF. Inset provides a magnified view of promoter
and TTS regions. (C) The 500 most significant Runx2 peaks, based on MACS [22] significance (P< 1× 10-10) were used for de novo motif discovery. A Runx2
motif (position weight matrix, top) with strong statistical confidence (P= 4.7 × 10-200) was determined using MEME (MEME suite version 4.7.0) [24]. The known
Runx motif (MA0002.2, bottom) in JASPAR [26] was used for comparison using TOMTOM [24]. As shown in (B), the distribution of de novo Runx2 motifs
among categories of genomic locations was determined using FIMO [24] at a significance threshold of P < 10-4. (D) Probability plot of the distribution
of Runx2 peaks indicating the distances of Runx2 motifs to the peak centers in the top, middle, and bottom third of Runx2 peaks (ranked by MACS
scores) versus the probabilities of finding de novo Runx2 motifs at given positions relative to peak center.
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Runx2 occupancy in genic contexts was also observed in
comparison with Runx2 motifs (Figure 2B). A de novo
Runx2 motif (Figure 2C, top) was discovered using MEME
[24] on the highest-ranked (by P-value) 500 ChIP-Seq
peaks and was then scanned using FIMO [24] (version
4.7.0) over the mouse genome. Notably, analysis by MEME
did not discover a significantly enriched secondary motif
associated with Runx2 peaks. Despite the nearly random
distribution of Runx2 motifs throughout the genome,
Runx2 occupancy in differentiating osteoblasts is character-
ized by associations with promoters, exons, introns and
other genic elements. These associations are perhaps due
to epigenetic factors, including chromatin conformation
and accessibility, along with co-factors, and suggest that
the presence of a Runx motif does not necessarily indicate
the physical association of Runx2. Interestingly, the distri-
bution of Runx2 occupancy among classes of genomic ele-
ments is similar to that of CTCF (Figure 2B), a ubiquitous
transcription factor that exhibits a broad spectrum of DNA
binding in many cell lines [25].
The de novo Runx2 motif (Figure 2C, top) was scanned
over all ChIP-Seq peaks called by MACS [22] from ChIP-
Seq reads collected from day 9 MC3T3 cells, and a histo-
gram of the distance between the peak summit and the
highest-scoring motif instance was collected. The distribu-
tion in Figure 2D is characterized by a sharp peak for
Runx2 motifs at the summits of ChIP-Seq peaks. Using
TOMTOM [24] it was determined that the de novo Runx2
motif was similar (E-value = 2.6 × 10-4, q-value = 2.6 × 10-4)
to the JASPAR MA0002.2 RUNX motif [26] (Figure 2C,
bottom) and both motifs share the core TGTGGT se-
quence with the known Runx2 binding consensus.
Genome-wide Runx2 occupancy reveals distinct positional
and temporal binding patterns
We grouped Runx2 peaks based on the presence or ab-
sence of Runx2 binding at specific time points during
differentiation (Figure 3A, off/on). The resulting seven
distinct clusters reflected the dynamics of Runx2 bind-
ing in relation to the progression of osteoblastogenesis
(Figure 3A). In Figure 3B, the mean ChIP-Seq read dens-
ities (that is, peak intensities) of the clustered Runx2 peaks
were plotted to compare their relative enrichments.
The seven clusters differed in the numbers and inten-
sities of Runx2 peaks (Figure 3A). The largest group was
cluster 6, which exhibited the presence of peaks primarily
at day 9. This finding is consistent with day 9 representing
committed osteoblasts with the highest amount of cellular
Runx2 protein (Figure 1B) and therefore the greatest num-
ber of Runx2 peaks (Figure 3B). The strongest Runx2 peak
intensities were found in cluster 1 reflecting regions that
were bound by Runx2 constitutively throughout osteoblast
differentiation (Figure 3B). The weakest Runx2 peak inten-
sities among the three time points occurred at the peaks
in cluster 7, with marginal enrichment of Runx2 at day 0.
It is noteworthy that the peaks in cluster 4 have the sec-
ond highest peak intensities at both days 9 and 28 (matrix
deposition and mineralization stages; Figure 3B). Cluster
5, like clusters 1 and 4, exhibited the highest peak inten-
sities on day 28, indicating their importance in maintain-
ing osteoblast phenotype.
Runx2 binding in each cluster was further examined for
distribution preferences of peaks in different genomic re-
gions, in contrast to the genome-wide distribution of ran-
dom 100 bp DNA fragments (detailed in Additional file 3;
Figure 3C). The random DNA fragments (grey bars in
Figure 3C) are distributed mainly in intergenic, intronic,
and upstream regions. When compared to the random con-
trol, we observed that the distribution of Runx2-enriched
peaks was biased towards gene regions (exons, introns, pro-
moters, TTS regions, upstream regions). In contrast, Runx2
binding in the intergenic regions is lower than the ran-
dom control (Figure 3C). In promoters and exons, all
clusters showed the highest enrichment over random
binding, suggesting strong regulation by Runx2 at these
genomic regions.
To further explore the relationship between Runx2
peaks and peak-associated genes in osteogenic differenti-
ation, we performed functional annotations for the peaks
in the seven clusters using GREAT (Genomic Regions En-
richment of Annotations Tool; Figure 3D). Gene Ontology
(GO) terms associated with the largest clusters are shown
in Figure 3D. Runx2 binding in cluster 1 yielded GO terms
of general biological processes such as protein folding and
RNA metabolism (detailed in Additional file 4). Cluster 4
peaks at days 9 and 28 were frequently related to the GO
terms of osteoblast differentiation, bone developmental pro-
cesses, and osteogenic signaling pathways. These terms often
included differentiation-related and well-known Runx2 tar-
get genes, such as Runx2, Bsp/Ibsp, and Osx/Sp7 (Additional
file 4). Similarly, cluster 6 (day 9) peaks often associated with
bone formation and extracellular matrix organization. The
annotation of other smaller clusters is shown in Additional
file 5. For examples, cluster 3 peaks were associated with
apoptosis, programmed cell death, and DNA damage; clus-
ter 7 containing peaks found only in day 0 was linked with
negative regulation of cell cycle control and the phenotypes
of non-osseous mesenchyme-derived cells (Additional files 4
and 5). These functional annotations associated with Runx2
peaks are generally consistent with the progression of
MC3T3-E1 differentiation, supporting a temporal transcrip-
tion network programmed by Runx2.
Runx2 binding patterns at osteogenic genes are
predictive of potential Runx2 targets
To discover previously unknown Runx2 target genes, we
first determined the Runx2 binding patterns of well-known
Runx2 target genes found in differentiation cluster 4; for
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example, Runx2, Osx/Sp7, and Ocn/Bglap2 (Figure 4A;
Additional file 6), and Bsp/Ibsp (Additional file 7). For these
genes Runx2 binding was distributed in promoters, the gene
body (introns/exons) and sites distal from the gene body.
Furthermore, Runx2 enrichment increased in the loci of
these genes during osteoblast differentiation at matrix and
mineralization stages. We then examined the genes associ-
ated with cluster 1 peaks (Additional file 8), and identified
genes, including Ezh2 (enchancer of zeste homolog 2)
(Figure 4B), with Runx2 binding profiles that displayed a
ubiquitous but increasing level of Runx2 occupancy. Ezh2 is
a component of PRC2 that epigenetically regulates gene ex-
pression by methylating histone H3 lysine 27 and was
recently found to be involved in commitment of mesenchy-
mal stem cells towards the osteoblast lineage [27]. The 5′
proximal promoter region of Ezh2 is bound by Runx2
(Figure 4B; Additional file 6) and shows an increase in reads
(occupancy) during differentiation. When Ezh2 mRNA
levels were measured during osteoblast differentiation, we
found that the highest expression occurred in proliferating
MC3T3-E1 cells, when the lowest amount of Runx2 binding
was observed (Figure 4C). The striking decrease in Ezh2
mRNA levels with increased Runx2 binding suggests that
the transcription of Ezh2 is potentially regulated by Runx2.
Genes regulated by Runx2 exhibit distinct Runx2 binding
profiles
To characterize the Runx2 binding profiles in genes that
are transcriptionally regulated by Runx2, we performed
gene expression profiling at day 9 in MC3T3-E1 cells
treated with control (Scr) short hairpin RNA (shRNA) or
a Runx2-specific shRNA (shRunx2) that knocks down
Runx2 expression. Runx2 protein levels decreased by 80%
in cells treated with shRunx2 (Additional file 9). This
knockdown in turn inhibited expression of differentiation
marker genes and osteoblastogenesis as demonstrated by
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decreased Alp staining (Additional file 9). We found 159
genes whose expression was responsive to Runx2 knock-
down, with |log2(IshRunx2/IScr)| > 1.5, and a false discovery
rate (FDR) <0.05, where I is the measured normalized
probe-set intensity. These genes included 115 up- and 44
down-regulated genes (Figure 5A). The 15 genes most re-
sponsive to Runx2 knockdown (Table 1) included the
well-defined Runx2 targets Ocn/Bglap2, Bsp/Ibsp, and
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Figure 5 Correlation of Runx2 occupancy and Runx2-reponsive genes identifies novel targets. (A) Expression levels of genes responsive to
Runx2 silencing in differentiated MC3T3-E1 cells. Values are plotted as the log2(expression level) from shRunx2-expressing cells (vertical axis) versus control
shRNA expression (horizontal axis). Each point represents mean mRNA expression level from three independent biological replicates. Several representative
genes are labeled. Diagonal lines demarcate the threshold for significant increase or decrease (≥1.5-fold) in expression. (B-D) Runx2 peaks associated with
upregulated (Up), downregulated (Down), or unchanged (Non-responsive) gene expression upon Runx2 knockdown were compared by: average peak
number per gene (B), and peak distribution (C) and fold change of peak signals (d9 versus d0) across genomic locations (D) with shRunx2 non-responsive
genes as a control. In (B), three groups were compared to non-responsive genes: all peaks in shRunx2-regulated genes (All peaks), all peaks present at day
9 in shRunx2-regulated genes (D9 peaks), and all peaks present at day 0 in shRunx2 regulated genes (D0 peaks). Values are mean ± SEM (B,D) and statistical
significance (*P< 0.01, **P< 0.05) determined by Mann-Whitney test (B,D) or Fisher’s exact test (C). (E) Runx2 enrichment across gene bodies (±10 kb) of
genes downregulated (Down), upregulated (Up), and unchanged (Non-responsive) by shRunx2 treatment at day 9. Mean signal ratios (IP/Input) at each
genomic region were determined using PeaksToGenes. Error bars represent SEM. (F) Mean phyloP conservation scores of Runx2 motifs associated with
genes significantly (fold change ≥1.5, FDR <0.05) downregulated (Down), upregulated (Up), or unchanged (Non-responsive) upon shRunx2-treatment.
Conservation of Runx2 motifs was compared between shRunx2 downregulated and upregulated genes and length-matched non-responsive genes
(Non-responsive, Down and Up, respectively) and statistical significance determined (**P< 0.05) by Kolmogorov-Smirnov test.
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Mmp13, which are known to be activated by Runx2 [5].
Notably, the genes most upregulated by shRunx2 have not
been characterized as Runx2 targets (Table 1) except for
Usp18, which encodes a protein involved in the ubiquitin
degradation pathway [28].
We characterized the relationship between Runx2 oc-
cupancy and genes affected by shRunx2 knockdown,
compared to non-responsive genes. The number of
peaks, genomic distribution of peaks, and fold change of
peak signals were compared among the gene groups at
days 0 and 9 (Figure 5B-D). Genes that were downregu-
lated by shRunx2 at both days 0 and 9 had more Runx2
peaks when compared to the control non-responsive
genes (Figure 5B). It should be noted, however, that
shRunx2 downregulated genes are longer than the up-
regulated genes (Additional file 10). This finding was
also observed when we included the Runx2 binding pro-
files at day 28 for Runx2-regulated genes (Additional file
10). In contrast, the shRunx2 upregulated genes that ap-
peared on day 9 had fewer Runx2 peaks compared to
control genes (Figure 5B). There were also significant
differences in overall peak distribution between shRunx2
responsive genes and control (Figure 5C). Genes that were
downregulated tended to exhibit more intronic and inter-
genic enrichment of Runx2 peaks, while shRunx2 upregu-
lated genes were strongly enriched in intergenic but
reduced in intronic binding. We further examined the dis-
tribution of Runx2 peaks in up- and down-regulated genes
as a function of changes in Runx2 binding during differen-
tiation from days 0 to 9 (Figure 5D). The fold change in
day 9/day 0 peak signals showed increased Runx2 binding
predominantly at upstream and promoter regions for the
shRunx2 downregulated genes; in shRunx2 upregulated
genes, Runx2 binding diminished in the introns and
showed no significant change in promoter regions. There-
fore, shRunx2 downregulated and upregulated genes ex-
hibited distinct preferences for Runx2 binding in genomic
loci as reflected by peak distributions in Figure 5B,C, and
in relation to differentiation (Figure 5D).
To complement the above analysis examining the
genome-wide distribution of Runx2 responsive peaks, we
used the PeaksToGenes program [29] to determine the
enrichment of day 9 Runx2 signals at defined intervals
within and surrounding the gene bodies (Figure 5E). For
shRunx2 downregulated genes, Runx2 binding had the
strongest enrichment surrounding TSSs, which includes
proximal promoter, 5′ UTR, exons and introns all within
five contiguous deciles (Figure 5E; Additional file 11).
This analysis demonstrated that, of genes affected by
shRunx2, 66.1% of upregulated genes have a low level
of Runx2 binding (cluster V in Figure S5B in Additional
file 11) but most downregulated genes (69.1%) have
higher level intensities of Runx2 binding (Figure S5A,B
in Additional file 11). This finding shows that Runx2 re-
sponsive genes at day 9 (shRunx2/Scr) are primarily reg-
ulated by Runx2 surrounding TSSs.
As another computational analysis, EMBER (Expect-
ation Maximization of Binding and Expression pRofiles)
[30] was used to relate measured changes in gene ex-
pression to the spectrum of Runx2 occupancy observed
during osteoblast differentiation (Figure 3B,C; Additional
file 12). In analogy with discovering a sequence motif
from a collection of functionally related DNA sequences,
EMBER optimizes an ‘expression pattern’ from a collec-
tion of genes related by patterns of transcription factor
binding and uses this motif to determine which genes
are regulatory targets of the transcription factor (details
of EMBER are summarized in Additional file 3). Using
this approach, we discovered and compared expression
patterns from different sets of Runx2 binding regions
(Figure 3). The Runx2 peaks were partitioned into 42
subsets of Runx2 binding regions (7 clusters with 6 gen-
omic location categories) and it was observed that all
groups of Runx2 binding show a correlative relationship
to gene expression during osteoblast differentiation
(Additional file 12). We noted, however, that intronic
Runx2 binding regions - for all time-dependent patterns
of Runx2 occupancy - are less informative than other
groups, indicating that intronic Runx2 binding may be
less useful than binding at other class elements as a pre-
dictor of gene regulation.
Finally, downregulated and upregulated genes were
compared on the basis of their evolutionary conservation
(Figure 5F). Functional genomic elements are often char-
acterized by conservation, which has been used to guide
Table 1 Top 15 genes upregulated or downregulated during
shRunx2 treatment when compared to scramble shRNA
Down Up
Symbol Fold change Symbol Fold change
Phex 0.26 I830012O16Rik 4.73
H19 0.36 Ifi27l2a 3.83
Ibsp 0.46 Oas2 3.78
Mmp13 0.46 D14Ertd668e 3.62
Mid2 0.49 Ifit3 3.37
Edil3 0.50 Gm12250 3.27
Tnfrsf19 0.53 Ifit1 3.25
Bglap2 0.56 Ly6c1 3.24
C87414 0.56 Usp18 3.09
Gpr116 0.56 BC023105 3.05
Pdlim1 0.57 Iigp1 3.05
Hs3st3a1 0.57 Ddx60 2.88
Id3 0.58 Gm4951 2.87
Chac1 0.58 Ly6a 2.87
Il33 0.58 Ly6c2 2.85
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the prediction of transcription factor binding sites
[31,32]. This finding has been shown to distinguish func-
tionally verified from un-verified binding sites in a large-
scale study of transcription factor binding site function
on human promoters [33]. For each ChIP-Seq peak, a
Runx motif was used to identify the single most likely
Runx2 binding site and the mean phyloP score [34] (for
conservation among 30 vertebrate species) across the
binding sites was computed. For each gene, phyloP
scores were averaged among all ChIP-Seq peaks that
were associated with individual genes to give an average
measure of Runx2 conservation. We found that genes
downregulated by shRunx2 had Runx2 binding se-
quences that were more conserved than those in upreg-
ulated or non-responsive genes (Figure 5F), suggesting
that Runx2 regulation may be more evolutionarily con-
served in genes that are activated by Runx2 during
osteoblastogenesis.
Taken together, the complementary methods described
above suggest that Runx2 employs different mechanisms to
regulate gene expression: 1) shRunx2 downregulated genes
show increased Runx2 binding at promoter and far up-
stream regions; and 2) based on EMBER, intronic binding
does not imply Runx2-mediated gene regulation to the same
degree as Runx2 binding at promoter, exon and upstream
regions. Thus, during the normal course of osteoblast differ-
entiation, Runx2-activated genes (shRunx2 downregulated)
are regulated through both promoter and non-promoter re-
gions; and regulation of Runx2 repressed genes (shRunx2
upregulated) also occurs in promoter and other genomic re-
gions, but with less Runx2 binding.
Novel genes regulated by Runx2 through distinct
regulatory elements
Among potential Runx2 targets, we identified Tnfrsf19
(tumor necrosis factor receptor superfamily, member
19), which is involved in bone formation as a Wnt-
responsive regulator of mesenchymal stem cell com-
mitment to osteoblastic lineage [35]. Tnfrsf19 exhibited
enrichment of Runx2 binding to the promoter as well as
intronic regions (Additional files 6 and 13). During dif-
ferentiation of osteoblasts, Tnfrsf19 mRNA levels in-
creased dramatically more than 100-fold from day 0 to
day 9 (Figure S7A in Additional file 13). Consistent with
Affymetrix data, depletion of Runx2 resulted in signifi-
cant decreases in Tnfrsf19 expression, indicating direct
Runx2 regulation (Figure S7B in Additional file 13). We
found that Runx2 occupancy was increased at intronic
and promoter regions of the Tnsrsf19 locus during osteo-
blast differentiation (Figure S7C in Additional file 13).
Adamts4 and Crabp2 were selected for further ana-
lyses based on their responsiveness to shRunx2 (with
fold change cutoff of 1.3; Additional file 14) and their
Runx2 binding patterns predominantly in non-promoter
regions. To test the functionality of Runx2 binding at these
putative regulatory regions, we cloned non-promoter Runx2
binding regions and measured transcriptional activity
by luciferase reporter assay. Adamts4 is expressed in
osteoblasts and osteocytes and encodes an enzyme that
degrades aggrecan [36,37]. Runx2 exhibits multiple peaks
across the Adamts4 locus, with increased occupancy
during osteoblast differentiation (Figure 6A; Additional
file 6). Adamts4 expression during osteoblast differenti-
ation was increased at day 9 and remained steady to day
28 (Figure 6B). Knockdown of Runx2 suppressed the ex-
pression of Adamts4 (Figure 6C) by 40%, supporting
Adamts4 as a direct target of Runx2 during osteoblasto-
genesis. We characterized the functional activity of two
prominent Runx2 binding regions, peak A in intron 1 and
peak B in the last exon (Figure 6A). The peak A region
increased luciferase activity in MC3T3-E1 cells by over
20-fold. In contrast, peak B functioned as a suppressor
of luciferase activity (Figure 6D). These results indicate
that the two Runx2 sites can function as a positive and
negative regulator of Adamts4; however, the weaker,
negative regulation by peak B on the luciferase reporter
may be due to the lack of a native chromatin context.
The large increase in luciferase activity observed from
peak A is consistent with a previous study that demon-
strated Runx2 upregulates ADAMTS4 in human SW1353
chondrosarcoma cells [38]. Here we established in osteo-
blasts that Runx2-mediated upregulation of Adamts4 can
occur at non-promoter regulatory elements, and is not re-
stricted to the proximal promoter region as previously
shown [38].
Crabp2 is a cytoplasmic retinoic acid binding protein
previously reported to be upregulated during osteoblasto-
genesis [39]. We observed that Runx2 constitutively occu-
pies the Crabp2 locus in the first intron, while binding
increases upstream and downstream of the Crabp2 gene
body during differentiation (Figure 6E; Additional file 6).
Crabp2 was upregulated during MC3T3-E1 cell differenti-
ation and knockdown of Runx2 decreased Crabp2 mRNA
level (Figure 6F). In proliferating cells, peak regions C, D
and E demonstrated minimal luciferase reporter activ-
ity. However, in differentiating cells, all peaks exhibited a
significant increase of luciferase activity, with peak region D
showing a more than 30-fold activation (Figure 6G). The
knockdown of Runx2 reduced luciferase activity (Figure 6H),
further supporting the function of these regions in mediat-
ing Runx2 regulation of Crabp2.
These findings of novel genes bound and regulated by
Runx2 through different types of genomic elements sup-
port an emerging concept that non-promoter elements
can regulate gene transcription. Our results also indicate
that Runx2 mediates complex fine-tuning of gene expres-
sion in osteoblasts by both activating and repressing regu-
latory elements that are located in non-promoter regions.
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Discussion
Through comprehensive genomic analysis of Runx2 by
ChIP-Seq, we describe widespread Runx2 binding through-
out the genome of differentiating osteoblasts. In addition
to Runx2 interaction at promoters, we find Runx2 binding
in non-promoter regions regulating novel targets that are
silenced or expressed at different stages of osteoblast dif-
ferentiation. Runx2 peaks cluster into temporal and func-
tional categories associated with genes in a broad range of
cellular programs, including bone development, negative
regulation of proliferation, active matrix formation and
mechanisms for mineral deposition that reflect the progres-
sion of osteogenesis. Our data have identified new Runx2-
regulated genes (Tnfrsf19, Adamts4, Crabp2, and Ezh2) that
have established roles in bone formation, and more import-
antly, have extended the understanding of Runx2-mediated
gene regulation to a broader range of cellular functions dur-
ing osteoblast differentiation.
Runx2 binding patterns identify stage-dependen
t osteogenic programs
Time-dependent Runx2 binding patterns underlie the dy-
namic gene regulation by Runx2 during osteoblastogene-
sis. We identified a large number of peaks, consistent with
the increasing protein levels of Runx2 from the early
osteoprogenitor to the mature osteoblast/osteocyte. The
results from binary clustering, together with subsequent
GO term analyses by GREAT, identified many categories
associated with skeletal development and bone homeosta-
sis. These findings support our initial hypothesis that dis-
tinct binding patterns of Runx2 at different stages of
osteoblastogenesis have novel functional implications.
Our clustering analysis partitioned Runx2 peaks into two
main categories: less variable steady-state binding (cluster
1, ubiquitous peaks) and more dynamic binding groups
(clusters 2 to 7, stage-specific clusters). Steady-state binding
of Runx2 persists from proliferative pre-osteoblasts to dif-
ferentiating osteoblasts with binding signals plateauing dur-
ing matrix deposition and mineralization stages. Peaks in
this category represent genes related to housekeeping
processes such as protein folding, negative regulation of
mitotic cell cycle, and mRNA catabolism and processes not
previously related to Runx2 (Additional file 4). The GO
terms associated with stage-specific clusters include nega-
tive regulators of other cell lineages (that is, fat and smooth
muscle cells) as well as positive regulators of osteogenesis.
Thus, dynamic Runx2 binding primes, enhances and stabi-
lizes the osteoblast phenotype as well as suppresses non-
osteoblast lineages. Many Runx2 bound genes in cluster 4
(days 9 & 28, differentiation) have been demonstrated to
contribute to in vivo bone formation [40]. Thus, the gen-
omic profiling of Runx2 binding in our in vitro model sys-
tem is consistent with the known properties of Runx2
in bone formation. More importantly, our profiling re-
veals pathways previously unknown to be controlled by
Runx2 underlying biological mechanisms of general cellular
processes.
Runx2 binding functions at both non-promoter and
promoter regions
Only a small proportion of sequence-specific transcription
factors, such as Myc, have narrow distributions of binding
around proximal promoters of genes [41-44]. In contrast,
non-promoter binding is recognized for other transcrip-
tion factors, including STAT1, RUNX1, ERα, CTCF, and
HNF4α [41,45-49]. In a previous study, overexpression of
Runx2 in prostate cancer cells revealed extensive non-
promoter binding [50]. In our study, endogenous Runx2
binding across the genome was characterized during os-
teoblastogenesis. We found that over 70% of Runx2 occu-
pancy was localized to non-promoter regions (intergenic,
intron, exon, TTS, and upstream regions that consti-
tute the bulk of the genome) during the differentiation of
osteoblasts. From days 0 to 9 there was a two-fold in-
crease in the number of non-promoter peaks, indicating a
functional association with the differentiation process.
Runx2-dependent regulation through non-promoter peaks
around the Adamts4 and Crabp2 genes provided direct
evidence that non-promoter binding of Runx2 controls
gene expression.
Although we have demonstrated the importance of
non-promoter Runx2 binding events, Runx2 peaks at
(See figure on previous page.)
Figure 6 Non-promoter association of Runx2 regulates novel targets Adamts4 and Crabp2. (A) Increasing Runx2 enrichment was observed
in the first intron (peak A, boxed region) and last exon (peak B, boxed region) of the Adamts4 locus during osteogenic differentiation. (B) Adamts4
mRNA levels (normalized to Hprt1) were significantly upregulated (P< 0.05) in differentiating MC3T3-E1 cells (days 9 to 28) when compared to proliferating
cells (day 0). (C) Runx2 knockdown (shRunx2) decreases Adamts4 expression, compared to a scrambled shRNA (Scr) control (**P< 0.05). (D) DNA sequences
identical to peak regions A and B were cloned into individual pGL2-SV40-Luc reporters and relative luciferase activity was measured in transfected MC3T3-E1 cells
and significant increases and decreases (*P<0.01) in luciferase activity were observed for peak A and B reporters, respectively. (E) Increasing Runx2 enrichment
was observed up- (peak C) and downstream (peaks D and E) of the Crabp2 locus during osteogenic differentiation. (F) Crabp2 expression increases during
differentiation. Knockdown of Runx2 (by shRunx2) significantly reduces (**P<0.05) the endogenous expression of Crabp2 (right panel). (G) DNA sequences
identical to peak regions C, D and E were cloned into individual pGL2-SV40-Luc reporters and relative luciferase activity was measured in transfected MC3T3-E1
cells at days 0 and 7 (*P<0.01). (H) Runx2 knockdown by inducible shRNA results in a significant decrease (**P<0.05) of luciferase activity mediated by peak C
and E regions and a downward trend (P=0.08) in luciferase activity regulated by peak D region. Statistical significance for all experiments was determined by
Student’s t-test from mean±SEM from three biological replicates.
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promoter regions have critical regulatory roles as well.
In our data, Runx2 occupancy has the highest enrich-
ment at promoter regions when compared with other
genomic locations. Examples of this regulatory mode
can be seen in some well-characterized Runx2 targets
such as Bsp and Ocn, in line with established evidence
that Runx2 can regulate these genes in a promoter-
dependent manner [51-54]. The genes downregulated
upon Runx2 silencing also displayed a clear enrichment
of Runx2 signal at promoter regions (Figure 5B), exem-
plified in Tnfrsf19.
Gene expression in different biological settings is influ-
enced by higher order three-dimensional chromatin
complexes that involve looping of promoter and non-
promoter elements, blurring the distinction of defined
regulatory regions [55,56]. It is plausible that some
Runx2 peaks in promoter and non-promoter regions
may serve as nucleation sites for modifications of chro-
matin structures necessary for gene expression. Further-
more, transcription factors can interact with RNA
polymerase II, CTCF, and other factors via higher-order
chromatin conformations [55,57,58]. During osteoblasto-
genesis, Runx2 exhibited a distribution pattern among
genomic elements similar to that of CTCF, suggesting
that, like CTCF, Runx2 may have a functional role that
extends beyond direct regulation of transcription. Con-
sistent with this idea, Runx2 is able to form discernible
foci associated with the nuclear matrix: a nuclear frame-
work for organizing higher order chromatin structures.
Runx2 truncated of the NMTS (nuclear matrix-targeting
signal) domain results in diminished nuclear matrix as-
sociation and disrupted expression of Runx2 target genes
[59]. It is also noteworthy that the genes upregulated
upon Runx2 knockdown have preferential Runx2 bind-
ing in intergenic regions, indicating that distal elements
may have a regulatory role through long-range interac-
tions. In addition, Runx2 binding at distal regions may
contribute to chromatin remodeling through interacting
with chromatin-modifying enzymes, as has been well
documented at regulatory elements in osteoblasts and
other cell models [12,13].
The complexities of Runx2 binding and transcriptional
regulation
Runx2 displays complex binding patterns similar to other
lineage-specific transcription factors, such as PPAR-γ,
MyoD, and GATA3 [16-19]. By systematic annotation of
Runx2 peaks, multiple integrative analyses of gene expres-
sion combined with Runx2 binding profiles and direct
experimental validation of individual targets, we defined
Runx2 binding with biological outcomes during osteoblast
differentiation. These analyses revealed that, for a small
set of genes, the enrichment and binding patterns of
Runx2 were indicators of gene expression. Genes that have
decreased expression in the absence of Runx2 (by
shRunx2 treatment) have a greater number of Runx2
peaks and greater fold change of peak signal at promoter
and non-promoter regions when compared to non-
responsive and gene length-matched controls. In contrast,
genes upregulated by Runx2 knockdown tend to have
fewer Runx2 peaks and smaller relative fold changes in
peak signals when compared to controls. One notable
finding that arose from our analysis was that genes that
were downregulated in the absence of Runx2 had both a
greater evolutionary conservation of Runx2 binding sites
and tended to be longer than non-responsive and upregu-
lated genes. It is unclear why this particular subset of
genes (that is, genes normally activated by Runx2) would
retain these features throughout evolution; however, this is
an interesting point for future investigations. Although we
demonstrated that Runx2 binding influences gene expres-
sion, a proportion of Runx2 peaks were found to have no
direct function in transcriptional control of genes. This may
be due to efficient but not complete knockdown of Runx2
by viral-mediated shRNA. Alternatively, similar to other
transcription factors, many binding regions were found to
be nonfunctional in transactivating luciferase reporters [33].
This finding suggests that binding of transcription factors
may have a distinct function other than direct control of
gene expression, consistent with previously described non-
transcriptional functions and genome-organizing capabilities
of Runx2 [59,60].
Conclusions
Our findings provide a new level of understanding of the
Runx2-mediated transcription program as defined by
genome-wide Runx2 binding essential for osteoblasto-
genesis. Our data support that Runx2 functions at pro-
moter and non-promoter regions at both previously
known and novel targets. The impact of our study exam-
ining the global occupancy of endogenous Runx2 in dif-
ferentiating osteoblasts sets a framework for novel
mechanisms underlying bone biology.
Materials and methods
Cell culture
The calvaria-derived preosteoblast cell line MC3T3-E1
(Subclone 4) was obtained from ATCC (Manassas, VA,
USA) and maintained in ascorbic acid-free alpha-MEM
(Hyclone, Novato, CA, USA) supplemented with 10% fetal
bovine serum (FBS; Hyclone), 2 mM L-glutamine, 100 U/ml
of penicillin and 100 μg/ml streptomycin (Pen/Strep, Invi-
trogen, Carlsbad, CA,). To induce osteogenic differentiation,
complete alpha-MEM was supplemented with 280 μM
ascorbic acid and 10 mM beta-glycerophosphate (Sigma
Aldrich, St. Louis, MO, USA). Cells were maintained at 37°C
in a humidified 5% CO2 environment and media replaced
every 2 to 3 days for the duration of all experiments.
Wu et al. Genome Biology 2014, 15:R52 Page 12 of 17
http://genomebiology.com/2014/15/3/R52
RNA isolation and quantitative PCR
Total RNA was isolated using Trizol reagent (Invitrogen)
according to the manufacturers’ specifications. Total cel-
lular RNA treated by DNaseI (Zymo, Irvine, CA, USA)
was primed with random hexamers and reverse tran-
scribed into cDNA using Superscript First-strand cDNA
Synthesis Kit (Invitrogen) according to the manufac-
turer’s instructions. Gene expression was determined by
quantitative real time PCR (qPCR) using iQ™ SYBR Green
PCR Master Mix (BioRad, Hercules, CA, USA) in an ABI
Prism 7300 thermocycler (Applied Biosystems, Foster
City, CA, USA). For each gene, the expression level was
normalized to that of Hprt1 using 2-ΔΔCT method. Experi-
ments were performed in triplicate and results are pre-
sented as mean values ± SEM. Primers for qPCR reactions
were designed by FoxPrimer [61,62], and are available in
Additional file 15.
Runx2 knockdown and gene expression profiling
Lentiviruses carrying Runx2-shRNA and previously de-
scribed control Scramble-shRNA [63] were used to in-
fect MC3T3-E1 cells. Infected cells were subsequently
detected by green fluorescent protein, sorted and grown
to 90% confluency followed by osteogenic differentiation
for 9 days. Knockdown experiments were performed in
three biological replicates.
Microarray samples were handled following the manu-
facturers’ recommended protocols (Affymetrix, Santa
Clara, CA, USA). Briefly, RNA isolated from MC3T3-E1
cells (day 0 and 9 scramble shRNA, and day 9 Runx2
shRNA) were reversely transcribed into cDNA using WT
Expression Kit (Ambion, Austin, TX, USA), labeled and
fragmented with GeneChip WT Terminal Labeling and
Controls Kit. Labeled cDNAs were then hybridized to
GeneChip Mouse Gene 1.0 ST Array rev.4 using a Gene-
Chip Hybridization, Wash, and Stain Kit. Hybridization
signals were obtained by GeneChip Scanner (Affymetrix).
Microarray data were analyzed using Bioconductor (ver-
sion 2.11) packages affy and limma in R (version 2.15.1)
[64-67]. Briefly, after performing RMA (robust multichip
average) normalization of microarray expression levels
and filtering, differential expression was detected using a
Bayesian moderated t-test. The Benjamini-Hochberg FDR
[68] was applied to correct for multiple testing. The Affy-
metrix expression profiles were annotated to RefSeq genes
[23]. These expression data have been deposited in the
Gene Expresion Omnibus (GEO) database under acces-
sion number GSE53982.
Western blot
Nuclei extracts were prepared from MC3T3-E1 cells
using a protocol modified from Dignam et al. [69]. Pri-
mary antibodies and dilutions were: mouse anti-Runx2
monoclonal (Clone 8G5, MBL International, Woburn,
MA, USA; 1:1,000); rabbit anti-H3 3H1 monoclonal
(Cell Signaling, Danvers, MA, USA; 1:2,000). HRP-
conjugated secondary antibodies and dilutions were: goat
anti-mouse IgG (Santa Cruz, Dallas, TX, USA; 1:3,000);
goat anti-rabbit IgG (Santa Cruz; 1:3,000). Detection of
HRP was performed using a Western Lightning Plus Kit
(Perkin Elmer, Waltham, MA, USA) followed by expos-
ure onto Biomax Light film (Kodak, Rochester, NY,
USA).
Chromatin immunoprecipitation and high-throughput
sequencing
At days 0, 9, and 28 of differentiation, approximately 1 ×
108 MC3T3-E1 cells were washed with PBS (phosphate-
buffered saline) and then fixed on a plate with 1% for-
maldehyde for 8 minutes to crosslink DNA-protein com-
plexes. The fixed cells were washed with ice-cold PBS,
harvested, and pelleted. Nuclei extraction was performed
using a protocol modified from Dignam et al. [69]. Iso-
lated nuclei were sonicated using a Misonix S-4000
ultrasonic sonicator to obtain sheared chromatin ranging
from 0.2 kb to 0.6 kb. Sheared chromatin was used
for immunoprecipitation with Runx2 antibody (M-70,
Santa Cruz) [70] or immunoglobulin G (IgG) (12-370,
Millipore, Billerica, MA, USA) followed by purification
using Protein-G Dynabeads (Invitrogen). Precipitated chro-
matin was washed with solutions of increasing salt con-
centration, and eluted and subsequently uncrosslinked at
65°C. DNA was recovered by phenol/chloroform/isoa-
myl alcohol extraction followed by ethanol precipita-
tion. Libraries of purified DNA were generated using
Illumina SR adapters (Illumina, San Diego, CA, USA)
following the manufacturer’s manual. DNA libraries
were selected for inserted fragments of 200 ± 50 bp,
and single-end 36 base reads were generated on an Illu-
mina Genome Analyzer II at the UMASS Deep-Seq
core facility. Base calls and sequence reads were gener-
ated by Illumina CASAVA software (version 1.6; Illu-
mina). Two independent biological repeats of Runx2
ChIP-Seq libraries were prepared for each time point,
and two Input libraries were prepared with sonicated
DNA from day 9 MC3T3-E1 cells.
Analysis of ChIP-Seq data
Single-end 36 base sequences from Runx2 ChIP-Seq and
input libraries were mapped to the mouse genome (as-
sembly mm9) using Bowtie (version 0.12.8) [71]. Runx2
peaks and read counts were determined by MACS (ver-
sion 1.4.1) [22] using default settings. Runx2 peaks that
were significant at the P < 10-10 level were retained for
subsequent analysis. For each of the three time points in
our data, read counts were normalized to 10 million
reads. The UCSC genome browser [72] was used to
visualize Runx2 peaks.
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Runx2 binding regions were classified on the basis of
genomic location categories and annotated to known
RefSeq genes [23]. Runx2 peaks were grouped into seven
clusters based on the presence or absence of a peak.
Runx2 peaks in each cluster were analyzed for GO terms
using GREAT (version 2.0.2), using default association
rules between ChIP-Seq peaks and annotated genes [73].
The conservation of Runx2 motifs associated with the
genes responsive to shRunx2 were determined using
phyloP [34]. Statistical significance was determined using
Kolmogorov-Smirnov test.
PeaksToGenes [29,62] (Additional file 3) was used to
test Runx2 binding in relation to the genes from micro-
array analysis. PeaksToGenes defines genomic intervals
relative to all RefSeq genes, and in each window uses a
non-parametric Wilcoxon rank sum test to calculate the
probability and binding frequency. The comparisons
were individually made between each responsive group
and the non-responsive group to Runx2 shRNA. Runx2
binding and Runx2-mediated transcription control were
also evaluated by EMBER [30]. Analogous to discovering
a sequence motif from functionally related DNA se-
quences [24], EMBER optimizes an expression pattern
from a collection of genes’ expression data related by
profiles of transcription factor binding and uses this in-
formation to determine which genes are potential regu-
latory targets of the transcription factor. For a detailed
description of the PeaksToGenes and EMBER analysis,
please refer to Additional file 3.
Functional genomic elements can be characterized by
evolutionary conservation and have been shown to dis-
tinguish functionally verified from unverified transcrip-
tion factor binding sites on human promoters [33]. For
each ChIP-Seq peak (combined from day 0, 9, and 28
datasets), a Runx motif was used to identify the single
most likely Runx2 binding site and the mean phyloP
score [34] (for conservation among 30 vertebrate spe-
cies) across the binding sites was computed. In order
to compare conservation among genes that fell into
different regulatory groups (shRunx2 downregulated, up-
regulated and non-responsive genes) based on our ex-
pression microarray measurements, phyloP scores were
averaged among all ChIP-Seq peaks that were associated
with individual genes to give an average measure of
Runx2 conservation for each gene. To minimize the
effect of gene length on Runx2 binding analysis, we
compared the conservation of shRunx2-downregulated and -
upregulated genes to randomly sampled, length-matched
non-responsive genes. Statistical significance was deter-
mined by pair-wise conservation comparisons using
Kolmogorov-Smirnov test.
The raw sequences and peak-related files in BED and WIG
formats representing processed data have been deposited in
the GEO database under accession number GSE54013.
Luciferase assays and plasmid reporters
Selected Runx2 peak regions were cloned with MluI
combined with BglII or XhoI into a pGL2-SV40-Luc re-
porter (Promega, Fitchburg, WI, USA). Primers used in
cloning are listed in Additional file 16. A pGL2-SV40-
Luc reporter with minimum SV40 promoter was used as
mock control. Reporter plasmids with Runx2 peak regions
and pGL2-SV40-Luc empty vector were co-transfected
with pcDNA3.1-Runx2-WT or pcDNA3.1-EV into MC3T3
cells. Transfected cells were then differentiated for 7 days
before luciferase activities were determined by Dual-Glo
Luciferase Assay Kit (Promega). A second set of luciferase
assays was done in differentiating MC3T3-E1 cells stably
infected with a doxycycline-inducible pLKO-puro-Tet-on-
Rx2shRNA lentiviral vector. This vector was constructed
by re-cloning a previously validated Runx2 shRNA se-
quence [63] to Tet-pLKO-puro plasmid (catalog number
21915, Addgene, Cambridge, MA, USA). Luciferase activ-
ities from MC3T3-E1 cells treated with or without 2.5
μg/ml doxycycline were examined at day 7 after differenti-
ation (Figure 6).
Additional files
Additional file 1: Table S3. Summary of MC3T3 Runx2 ChIP-Seq. This table
lists the read numbers and genome coverage of Runx2 ChIP-Seq libraries.
Additional file 2: Table S4. Distribution patterns of Runx2 peaks across
genomic locations. This table is related to Figure 2.
Additional file 3: Detailed description of ChIP-PCR, ChIP-Seq with
bioinformatics analysis, and supplemental figure legends.
Additional file 4: Table S5. GREAT Gene Ontology terms. This table
contains the top GO terms assigned by GREAT to clusters 1 to 7 defined
in Figure 3A.
Additional file 5: Figure S1. GO term analysis from GREAT for clusters
1 to 3 and 5 to 7 in Figure 3A. This is related to Figure 3.
Additional file 6: Figure S8. Validation of Runx2 peaks by ChIP-PCR.
This figure is related to Figures 4, 5 and 6.
Additional file 7: Figure S2. Runx2 peaks associated with Bsp gene
during differentiation. This figure is related to Figure 4.
Additional file 8: Table S6. Detailed annotation of Runx2 peaks. This
table is a meta-spreadsheet of Runx2 peaks annotated to RefSeq genes.
Additional file 9: Figure S3. Validation of Runx2 knockdown in MC3T3
cells. This figure is related to Figure 5.
Additional file 10: Figure S4. Additional characteristics of Runx2
binding in shRunx2 responsive genes. This figure is related to Figure 5.
Additional file 11: Figure S5. PeaksToGenes analysis of Runx2 occupancy
in Runx2 shRNA-responsive genes. This figure is related to Figure 5E.
Additional file 12: Figure S6. EMBER analyses of Runx2 binding in the
genes differentially regulated by Runx2 knockdown. This figure is related
to Figure 5.
Additional file 13: Figure S7. Validation of novel Runx2 target Tnfrsf19.
This figure is related to Figure 6.
Additional file 14: Table S7. Genes responsive to Runx2 shRNA. This
table lists the genes that are up- or down- regulated by shRunx2 treat-
ment in MC3T3 cells differentiated for 9 days.
Additional file 15: Table S1. qPCR and ChIP-PCR primers.
Additional file 16: Table S2. Cloning primers. This table contains the
primers used for plasmid construction.
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